HIGHLIGHTS
- who: Eun-mi Yu and collaborators from the Schar Cancer Institute, Fairfax, VA, USA have published the research: Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC), in the Journal: Uro 2023, of 23/Dec/2024
- what: Clear cell renal cell carcinoma comprises the most common histology for all renal cell carcinomas , and is the main focus of this review. The trial was designed to evaluate primary endpoints of PFS and OS in the ITT population, with objective response rate (ORR) as a key secondary endpoint. The trial was open-label and conducted across multiple . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.